Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Equity Income (2018 - 2022)

Arcturus Therapeutics Holdings (ARCT) has disclosed Equity Income for 5 consecutive years, with -$131000.0 as the latest value for Q2 2022.

  • For the quarter ending Q2 2022, Equity Income rose 60.06% year-over-year to -$131000.0, compared with a TTM value of -$515000.0 through Dec 2022, down 200.0%, and an annual FY2022 reading of -$515000.0, down 200.0% over the prior year.
  • Equity Income was -$131000.0 for Q2 2022 at Arcturus Therapeutics Holdings, up from -$384000.0 in the prior quarter.
  • Across five years, Equity Income topped out at $1.2 million in Q1 2021 and bottomed at -$384000.0 in Q1 2022.
  • Average Equity Income over 5 years is -$29923.1, with a median of -$131000.0 recorded in 2022.
  • Peak annual rise in Equity Income hit 865.64% in 2021, while the deepest fall reached 228.0% in 2021.
  • Year by year, Equity Income stood at -$47000.0 in 2018, then changed by 0.0% to -$47000.0 in 2019, then crashed by 112.77% to -$100000.0 in 2020, then plummeted by 55.0% to -$155000.0 in 2021, then grew by 15.48% to -$131000.0 in 2022.
  • Business Quant data shows Equity Income for ARCT at -$131000.0 in Q2 2022, -$384000.0 in Q1 2022, and -$155000.0 in Q4 2021.